DeepMed Research

BioNTech

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Employees: 6.1K

Market Cap: $20.7B

Website: http://www.biontech.de

Introduction: BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Clinical Trials

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: BNT116
Biological: BNT316
Biological: anti-B7-H3 antibody conjugated to topoisomerase I inhibitor
Biological: anti-HER3 antibody conjugated to topoisomerase I inhibitor
Biological: Cemiplimab
Drug: Docetaxel
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2021-12-02

Last Posted Date: 2025-05-07

Lead Sponsor: BioNTech SE

Target Recruit Count: 220

Registration Number: NCT05142189

Locations: 🇪🇸
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
🇩🇪
Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF), Frankfurt, Germany
🇪🇸
MD Anderson Cancer Center, Madrid, Spain

and more 36 locations

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Phase 2

Completed

Conditions: SARS-CoV-2 Infection
COVID-19
SARS-CoV-2 Acute Respiratory Disease
SARS (Disease)

Interventions: Biological: Monovalent BNT162b2 (B.1.617.2)
Biological: BNT162b2
Other: Observational
Biological: Monovalent BNT162b2 (B.1.1.529.1)
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Biological: Monovalent BNT162b2 (B.1.1.7)

First Posted Date: 2021-08-13

Last Posted Date: 2024-11-22

Lead Sponsor: BioNTech SE

Target Recruit Count: 1380

Registration Number: NCT05004181

Locations: 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸
North Texas Infectious Diseases Consultants, Dallas, Texas, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 32 locations

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Phase 3

Completed

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Biological: BNT162b2
Other: Placebo
Biological: BNT162b2 OMI
Biological: Combination BNT162b2 and BNT162b2 OMI
Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI

First Posted Date: 2021-07-09

Last Posted Date: 2023-06-13

Lead Sponsor: BioNTech SE

Target Recruit Count: 16385

Registration Number: NCT04955626

Locations: 🇺🇸
Wenatchee Valley Hospital, Wenatchee, Washington, United States
🇿🇦
Tiervlei Trial Centre, Cape Town, Western CAPE, South Africa
🇺🇸
Kaiser Permenente Medical Center Infectious Disease, Los Angeles, California, United States

and more 137 locations

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

Phase 2

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b2
Biological: BNT162b2s01

First Posted Date: 2021-07-02

Last Posted Date: 2022-09-21

Lead Sponsor: BioNTech SE

Target Recruit Count: 137

Registration Number: NCT04949490

Locations: 🇩🇪
University Hospital Heidelberg, Clinical Pharmacology, Heidelberg, Germany
🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
🇩🇪
University Hospital Frankfurt, Infectiology, Frankfurt, Germany

and more 1 locations

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

Phase 2

Completed

Conditions: SARS-CoV-2 Infection, COVID19

Interventions: Biological: BNT162b2

First Posted Date: 2021-05-21

Last Posted Date: 2024-10-09

Lead Sponsor: BioNTech SE

Target Recruit Count: 124

Registration Number: NCT04895982

Locations: 🇺🇸
Ochsner Medical Center Kenner, Kenner, Louisiana, United States
🇩🇪
Studiengesellschaft BSF UG., Halle (Saale), Germany
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

and more 21 locations

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

Phase 3

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b2

First Posted Date: 2021-03-25

Last Posted Date: 2022-12-23

Lead Sponsor: BioNTech SE

Target Recruit Count: 629

Registration Number: NCT04816669

Locations: 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States

and more 18 locations

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Phase 2

Completed

Conditions: SARS-CoV-2 Infection, COVID-19

Interventions: Biological: BNT162b2 20mcg
Biological: BNT162b2 30mcg
Other: Placebo

First Posted Date: 2021-03-25

Last Posted Date: 2023-12-19

Lead Sponsor: BioNTech SE

Target Recruit Count: 11837

Registration Number: NCT04816643

Locations: 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
SKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi, United States

and more 132 locations

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

Active, not recruiting

Conditions: Colorectal Cancer Stage II
Colorectal Cancer Stage III

Interventions: Procedure: Regular blood sample collection for ctDNA assessment

First Posted Date: 2021-03-24

Last Posted Date: 2025-04-11

Lead Sponsor: BioNTech SE

Target Recruit Count: 2200

Registration Number: NCT04813627

Locations: 🇩🇪
Centrum fuer Haematologie und Onkologie Bethanien, Frankfurt am Main, Germany
🇩🇪
Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany
🇩🇪
Medizinische Klinik III, Universitätsklinikum Bonn, Bonn, Germany

and more 71 locations

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Phase 2

Completed

Conditions: Maternal Immunization
COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b2
Other: Placebo

First Posted Date: 2021-02-15

Last Posted Date: 2024-12-06

Lead Sponsor: BioNTech SE

Target Recruit Count: 726

Registration Number: NCT04754594

Locations: 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain
🇪🇸
Hospital Quironsalud Barcelona, Barcelona, Spain

and more 79 locations

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Phase 3

Completed

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Biological: BNT162b2
Biological: BNT162b2.B.1.351

First Posted Date: 2021-01-19

Last Posted Date: 2022-12-22

Lead Sponsor: BioNTech SE

Target Recruit Count: 1574

Registration Number: NCT04713553

Locations: 🇺🇸
Clinical Research Consulting, Milford, Connecticut, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸
Amici Clinical Research LLC, Raritan, New Jersey, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy